Trial · NCT02359435
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
NCT02359435, Not applicable, Completed, Kaohsiung Veterans General Hospital.; results first posted 2016-02-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection. Trials, record NCT02359435. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02359435
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
- NCT number
- NCT02359435
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 440 participants, actual
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Reverse hybrid therapy, Standard triple therapy
- First posted
- 2015-02-10
- Last updated
- 2017-04-18
- Results first posted
- 2016-02-10
- Limitations and caveats
- The trial was performed in a single country
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants in Which H. Pylori Was Eradicated | at the 6th week after the end of anti- H. pylori therapy | Evaluate eradication outcome by endoscopy urease test and histology or urea breath test |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants in Which H. Pylori Was Eradicated | at the 6th week after the end of anti- H. pylori therapy | Intention to treat | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants in Which H. Pylori Was Eradicated | Reverse Hybrid Therapy | 206 | participants | ||
| Number of Participants in Which H. Pylori Was Eradicated | Standard Triple Therapy | 191 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Reverse Hybrid Therapy | 220 | |
| Overall Study | STARTED | Standard Triple Therapy | 220 | |
| Overall Study | COMPLETED | Reverse Hybrid Therapy | 216 | |
| Overall Study | COMPLETED | Standard Triple Therapy | 216 | |
| Overall Study | NOT COMPLETED | Reverse Hybrid Therapy | 4 | |
| Overall Study | NOT COMPLETED | Standard Triple Therapy | 4 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Reverse Hybrid Therapy | 15 | 220 | 15 |
| other | Nausea | Gastrointestinal disorders | Standard Triple Therapy | 6 | 220 | 6 |
| other | Dizziness | Nervous system disorders | Reverse Hybrid Therapy | 7 | 220 | 7 |
| other | Dizziness | Nervous system disorders | Standard Triple Therapy | 9 | 220 | 9 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Reverse Hybrid Therapy | ||
| Total, all-cause mortality | Standard Triple Therapy | ||
| Total, other adverse events | Reverse Hybrid Therapy | 22 | 220 |
| Total, other adverse events | Standard Triple Therapy | 15 | 220 |
| Total, serious adverse events | Reverse Hybrid Therapy | 0 | 220 |
| Total, serious adverse events | Standard Triple Therapy | 0 | 220 |
Source ClinicalTrials.gov
Papers31
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Reverse Hybrid Therapy vs Standard Triple Therapy: Number of Participants in Which H. Pylori Was Eradicated | Trial comparisons |
| Reverse Hybrid Therapy vs Standard Triple Therapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02359435
GET https://conductscience.org/api/trials/v1/NCT02359435/papers?page=2